No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

​Union Minister of Health and Family Welfare said that extensive studies by the Indian Council of Medical Research (ICMR) and All India Institute of Medical Sciences have conclusively established no linkage between COVID-19 vaccines and sudden deaths among adults post-COVID-19.

The Ministry noted that studies conducted by ICMR and the National Centre for Disease Control (NCDC) affirm that COVID-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects. The incidence of sudden cardiac deaths can result from a wide range of factors, including genetics, lifestyle, pre-existing conditions, and post-COVID complications. The ICMR and NCDC have been working together to understand the causes behind sudden, unexplained deaths, especially in young adults between the ages of 18 and 45 years.

Akashvani correspondent reports that to explore this, two complementary studies were undertaken using different research approaches-one based on past data and another involving real-time investigation. The findings of the first study have conclusively shown that COVID-19 vaccination does not increase the risk of unexplained sudden death in young adults. The second study is currently being conducted by AIIMS, New Delhi.

Early analysis indicates that heart attacks, or myocardial infarction, continue to be the leading cause of sudden death in this age group. The studies offer a more comprehensive understanding of sudden unexplained deaths in young adults in India. They also reveal that COVID-19 vaccination does not appear to increase the risk, whereas the role of underlying health issues, genetic predisposition and risky lifestyle choices does play a role in unexplained sudden deaths. Scientific experts have reiterated that statements linking COVID vaccination to sudden deaths are false and misleading, not supported by scientific consensus.

Related Posts

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

NEW DELHI—  Abbott, the global healthcare company, today announced the launch of XIENCE Skypoint in India. This is Abbott’s most advanced generation stent within the globally trusted XIENCE™ family of…

Top 30 pharma companies post 12% revenue growth in first nine months

Mumbai:  The aggregate financial performance of top 30 Indian pharmaceutical companies, with revenues of over Rs. 2,500 crore during 2024-25, remained under pressure during the first nine months of FY2025-26…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

Top 30 pharma companies post 12% revenue growth in first nine months

Top 30 pharma companies post 12% revenue growth in first nine months

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

Ludhiana police seize 56 kg ganja; courier warehouse under scanner

Ludhiana police seize 56 kg ganja; courier warehouse under scanner

AsterDMHealthcare-QCIL Merger mirrors Overwhelming Trust in Leadership

AsterDMHealthcare-QCIL Merger mirrors Overwhelming Trust in Leadership

DCGI asks drugmakers to stop GLP-1 obesity awareness ad campaigns

DCGI asks drugmakers to stop GLP-1 obesity awareness ad campaigns